Key Finding
Acupuncture combined with donepezil showed 35% greater clinical efficacy than donepezil alone for Alzheimer's disease, with significant improvements in cognitive function, daily living activities, and behavioral symptoms across all measured outcomes.
Researchers analyzed 12 clinical trials to determine whether combining acupuncture with donepezil (a common Alzheimer's medication) works better than donepezil alone for treating Alzheimer's disease (AD). As our population ages, Alzheimer's affects more people each year, creating significant challenges for patients, families, and healthcare systems.
The study examined nearly 1,000 patients across multiple research trials, looking at how well the combination therapy improved thinking abilities, daily functioning, and behavioral symptoms. Researchers evaluated outcomes using standard cognitive tests like the Mini-Mental State Examination and Montreal Cognitive Assessment, along with measures of daily living skills and behavioral problems.
Results showed that patients receiving both acupuncture and donepezil experienced significantly better outcomes than those taking donepezil alone. The combination therapy improved cognitive test scores, enhanced ability to perform daily activities, and reduced behavioral problems associated with Alzheimer's. Patients were 35% more likely to show clinical improvement with the combined approach. Cognitive assessment scores improved by an average of 3-6 points on standard scales, which represents meaningful functional improvement for patients.
These findings suggest that acupuncture may be a valuable complementary treatment for Alzheimer's patients already taking donepezil. The combination appears safe and may help preserve cognitive function and quality of life longer than medication alone. However, researchers note that larger, higher-quality studies are still needed to confirm these benefits.
If you're considering acupuncture for Alzheimer's disease, discuss it with your neurologist or primary care physician, and seek treatment from a licensed acupuncturist experienced in treating neurological conditions.
This systematic review and meta-analysis evaluated 12 randomized controlled trials examining acupuncture plus donepezil versus donepezil monotherapy for Alzheimer's disease treatment. Studies were retrieved from eight databases through October 2023, with outcomes analyzed using RevMan 5.4.1 software.
Key findings demonstrated statistically significant improvements favoring combination therapy across multiple validated outcome measures. Clinical efficacy rate showed 35% improvement (RR=1.35; 95% CI: 1.17-1.56; P<0.0001). Cognitive assessments revealed meaningful gains: MMSE scores increased by 3.28 points (95% CI: 1.81-4.75; P<0.0001) and MoCA scores by 6.04 points (95% CI: 4.76-7.32; P=0.00001). ADAS-Cog scores decreased by 3.57 points (95% CI: -3.94 to -3.20; P<0.00001), indicating improved cognitive capacity. Functional measures also improved significantly, with ADL scores decreasing by 2.52 points and BEHAVE-AD scores by 4.04 points (both P<0.001).
Clinical takeaway: Acupuncture as adjunctive therapy to donepezil demonstrates robust efficacy for improving cognitive function, daily living skills, and behavioral symptoms in AD patients, though higher-quality large-scale RCTs are warranted.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
📌 Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
📌 Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.